BriaCell Therapeutics Corp. War (BCTXZ) Fair Value 2026

BCTXZ · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, BriaCell Therapeutics Corp. War (BCTXZ) trades at $0.09. QOC: 4.4/10. Value Trap Risk: 24/100 (SAFE). 1/13 models active.

Key Facts

Ticker
BCTXZ
Price
$0.09
Quality Score
4.4/10
Value Trap Risk
24/100
Models Active
1/13
Last Updated
Strength: ML-RIV suggests +239.1% upside with 46% confidence
Risk: Below-average Quality Score of 4.4/10 signals weak fundamentals

Valuation Matrix

1 Intrinsic Value Models vs. Current Price ($0.09)

Core Models (Unlocked)
Model Fair Value Upside
ML-RIV
Medium Conviction
 $0.31 +239.1%

All Models Active

All 1 models are displayed above.

What Is BriaCell Therapeutics Corp. War (BCTXZ) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BriaCell Therapeutics Corp. War is potentially undervalued at its current price of $0.09. Based on our 13-model framework, BriaCell Therapeutics Corp. War's intrinsic value is estimated at a composite fair value of $0.31 — representing +239.1% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About BCTXZ?

1 of 13 models are currently active for BCTXZ. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BCTXZ Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, BCTXZ ranks #295 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a biopharma enterprise, BriaCell Therapeutics Corp. War operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating BCTXZ should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BCTXZ a Value Trap?

CirclFi's Value Trap algorithm assigns BCTXZ a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for BriaCell Therapeutics Corp. War. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BriaCell Therapeutics Corp. War is rated at 4.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BCTXZ valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BCTXZ's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BriaCell Therapeutics Corp. War Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

AZNAstraZeneca PLCQOC 10.0CPRXCatalyst Pharmaceuticals, Inc.QOC 10.0HRMYHarmony Biosciences Holdings, IQOC 10.0NVONovo Nordisk A/SQOC 10.0SIGASIGA Technologies Inc.QOC 10.0UTHRUnited Therapeutics CorporationQOC 10.0ZTSZoetis Inc.QOC 10.0RDYDr. Reddy's Laboratories LtdQOC 9.9

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About BriaCell Therapeutics Corp. War

What is BriaCell Therapeutics Corp. War's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, BriaCell Therapeutics Corp. War (BCTXZ) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value. The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BCTXZ overvalued or undervalued right now?

At $0.09, 1 of 1 active models suggest BCTXZ may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits BriaCell Therapeutics Corp. War's business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.4 mean for BCTXZ?

BriaCell Therapeutics Corp. War's QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BCTXZ?

CirclFi analyzes BCTXZ with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BCTXZ a value trap in 2026?

BriaCell Therapeutics Corp. War's Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns BriaCell Therapeutics Corp. War (BCTXZ) a Quality of Company score of 4.4/10 across 32 fundamental signals as of 2026-07-15.” Source: circlfi.com/stock/BCTXZ/ · Methodology